Abemaciclib metabolite M20

Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4/6 inhibitor for the treatment of cancer[1].

Product Specifications

CAS Number

[2138499-06-4]

Product Name Alternative

LSN3106726

UNSPSC

12352005

Target

CDK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cdk4-6-in-4.html

Purity

96.02

Solubility

DMSO : 5 mg/mL (ultrasonic)

Smiles

OCC1=NC2=C(F)C=C(C3=NC(NC4=NC=C(CN5CCN(CC)CC5)C=C4)=NC=C3F)C=C2N1C(C)C

Molecular Formula

C27H32F2N8O

Molecular Weight

522.59

References & Citations

[1]Morschhauser F, et al. Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study. Haematologica. 2021;106 (3) :859-862. Published 2021 Mar 1. |[2]Burke T, et al. The major human metabolites of abemaciclib are inhibitors of CDK4 and CDK6[J]. Cancer Research, 2016, 76 (14_Supplement) : 2830-2830.